FY2025 Earnings Estimate for TNGX Issued By Leerink Partnrs

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Analysts at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for Tango Therapeutics in a research report issued on Tuesday, November 4th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($0.92) for the year, up from their prior estimate of ($0.95). The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Leerink Partnrs also issued estimates for Tango Therapeutics’ FY2026 earnings at ($1.31) EPS, FY2027 earnings at ($1.81) EPS and FY2028 earnings at ($1.35) EPS.

A number of other equities analysts have also commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tango Therapeutics in a research report on Monday, October 27th. Guggenheim raised their target price on shares of Tango Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, October 24th. Piper Sandler started coverage on shares of Tango Therapeutics in a research report on Monday, August 18th. They issued an “overweight” rating and a $11.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Tango Therapeutics Stock Performance

TNGX opened at $8.01 on Friday. The stock has a fifty day moving average of $7.69 and a 200-day moving average of $5.59. The company has a market capitalization of $1.08 billion, a P/E ratio of -8.61 and a beta of 1.66. Tango Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $9.70.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.12. Tango Therapeutics had a negative return on equity of 60.80% and a negative net margin of 151.15%.The business had revenue of $53.81 million during the quarter, compared to the consensus estimate of $41.35 million.

Insider Buying and Selling at Tango Therapeutics

In related news, major shareholder Rock Ventures Iv L.P. Third sold 477,401 shares of the stock in a transaction that occurred on Thursday, October 23rd. The shares were sold at an average price of $10.15, for a total transaction of $4,845,620.15. Following the sale, the insider owned 13,386,574 shares in the company, valued at approximately $135,873,726.10. This trade represents a 3.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 3,472,501 shares of company stock worth $26,350,320. Corporate insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its stake in shares of Tango Therapeutics by 9.9% in the 1st quarter. Bank of New York Mellon Corp now owns 113,233 shares of the company’s stock valued at $155,000 after purchasing an additional 10,213 shares during the last quarter. XTX Topco Ltd boosted its stake in Tango Therapeutics by 115.7% in the first quarter. XTX Topco Ltd now owns 168,145 shares of the company’s stock valued at $230,000 after buying an additional 90,208 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Tango Therapeutics by 6.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 548,014 shares of the company’s stock valued at $751,000 after acquiring an additional 34,585 shares during the last quarter. Deutsche Bank AG raised its stake in Tango Therapeutics by 46.7% during the first quarter. Deutsche Bank AG now owns 53,788 shares of the company’s stock worth $74,000 after acquiring an additional 17,135 shares in the last quarter. Finally, Invesco Ltd. raised its stake in Tango Therapeutics by 138.8% during the first quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock worth $97,000 after acquiring an additional 40,983 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.